• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Automated Insulin Delivery: Tandem Diabetes Unveils Control-IQ+ Enhancements

by Jasmine Pennic 03/19/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– Tandem Diabetes Care, a leader in insulin delivery and diabetes technology announced the U.S. commercial launch of Control-IQ+ technology. 

– This update provides users with greater flexibility and control over their diabetes management. The expanded parameters and enhanced features of Control-IQ+ are designed to address a broader range of individual needs, making automated insulin delivery more accessible and effective.

Automated Insulin Delivery Technology 

Control-IQ+ is compatible with both the t:slim X2 insulin pump and the Tandem Mobi System, and is now available for individuals with type 1 diabetes ages 2 years and older, as well as adults with type 2 diabetes. New pumps pre-loaded with the updated software are now being shipped to new customers. Importantly, all eligible, in-warranty Tandem customers will receive access to the new features via a free, remote software update.

Control-IQ+ builds upon the foundation of Tandem’s existing Control-IQ algorithm, which already features:

  • Automated Insulin Adjustments: The system adjusts insulin delivery every 5 minutes based on predicted glucose values.
  • AutoBolus™ Feature: A unique AutoBolus™ feature calculates and delivers a correction bolus to help manage missed meal boluses.
  • Extended Bolus Capability: Control-IQ+ is the only AID algorithm that allows users to program extended boluses of up to 8 hours while automation is active.

“These new features allow for even greater levels of personalization and flexibility within our algorithm, while still receiving high marks for ease of use across a diverse population of users,” said John Sheridan, president and chief executive officer. “We are proud to offer this life-changing technology to millions more people living with diabetes.”

All eligible, in-warranty Tandem users can access the software update by logging into their Tandem Source account: https://source.tandemdiabetes.com.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Diabetes Management

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |